Hemochromatosis is not an autoimmune disease. It is a genetic disorder caused by inherited mutations that disrupt how your body regulates iron absorption, leading to a gradual buildup of iron in your organs. Unlike autoimmune conditions, where the immune system mistakenly attacks healthy tissue, hemochromatosis involves no immune system malfunction at all. The confusion is understandable, though, because hemochromatosis can produce symptoms that look remarkably similar to autoimmune diseases like rheumatoid arthritis.
Why Hemochromatosis Gets Confused With Autoimmune Disease
About two-thirds of people with hereditary hemochromatosis develop joint problems, and the way those joint problems show up can closely mimic rheumatoid arthritis. Patients report swollen hands, morning stiffness lasting up to an hour, and symmetrical joint involvement on both sides of the body. The classic pattern affects the second and third knuckle joints, but large and small joints alike can be involved. Even ultrasound imaging can be misleading: one published case report described a woman whose joint inflammation on imaging looked so much like early rheumatoid arthritis that it nearly led to a misdiagnosis. She had none of the textbook signs of hemochromatosis like abnormal liver enzymes, skin darkening, or diabetes.
Iron deposits in joints can also trigger a condition called pseudogout, where calcium crystals form in the joint cartilage and cause flare-ups of acute pain and swelling. This adds another layer of similarity to inflammatory autoimmune conditions, making it easy to see why patients and even clinicians sometimes land on the wrong diagnosis initially.
What Actually Causes Hemochromatosis
The most common form, hereditary hemochromatosis, follows a straightforward genetic pattern. You inherit two copies of a mutated gene called HFE, one from each parent. The most significant mutation, known as C282Y, accounts for 80 to 90 percent of cases with clinical disease. About 1 in 16 people of European descent carry a single copy of this mutation, but you need two copies to be at risk. The condition is most common in people of northern European ancestry, occurring in roughly 1 in 300 non-Hispanic white Americans and up to 1 in 150 people of northwestern European descent.
The HFE gene helps regulate a hormone called hepcidin, which acts as the body’s iron gatekeeper. Hepcidin controls how much iron passes from your gut into your bloodstream and how much iron gets released from your cells. When the gene is mutated, hepcidin levels drop too low, and the gate stays open. Your body absorbs more dietary iron than it needs and has no effective way to get rid of the excess. Over years, iron accumulates in your liver, heart, pancreas, joints, and skin.
There are also rarer juvenile forms caused by mutations in different genes that regulate hepcidin even more severely. These tend to cause iron overload earlier in life, sometimes in the teens or twenties, because hepcidin levels are extremely low.
How Iron Overload Damages the Body
Excess iron is directly toxic to cells. It generates reactive oxygen species, which are unstable molecules that damage cell membranes and DNA. Over time, this triggers a specific type of cell death called ferroptosis, where iron essentially poisons cells from within. The organs affected depend on where iron accumulates most heavily.
In the pancreas, ferroptosis kills insulin-producing beta cells, reducing your body’s ability to make and release insulin. When iron also builds up in the liver, fat tissue, and muscle, it impairs those tissues’ ability to respond to insulin. The combination of reduced insulin production and insulin resistance leads to diabetes. When skin darkening from iron deposits occurs alongside this diabetes, the condition has historically been called “bronze diabetes.”
Iron overload in the liver causes progressive damage that can lead to cirrhosis. In the heart, it can cause cardiomyopathy, where the heart muscle weakens. In the pituitary gland and reproductive organs, it disrupts hormone production, potentially causing impotence in men and early menopause in women. Joint and muscle pain are among the most common early complaints.
How This Differs From Autoimmune Liver Disease
One area where hemochromatosis and autoimmune disease genuinely overlap in clinical settings is liver damage. Both hemochromatosis and autoimmune hepatitis can cause chronic hepatitis and elevated liver enzymes, but the underlying mechanisms are completely different. In autoimmune hepatitis, the immune system produces inflammatory signals like interleukin-6 that actually increase hepcidin and ferritin while lowering iron levels in the blood. In hemochromatosis, the opposite happens: hepcidin is low, and transferrin saturation (a measure of how much iron is circulating in your blood) is high.
This distinction is one of the key ways doctors tell the two conditions apart. Transferrin saturation is typically low in autoimmune hepatitis and elevated in hemochromatosis.
Secondary Iron Overload Without Genetics
Not all iron overload is hereditary. People who receive frequent blood transfusions for conditions like thalassemia, sickle cell anemia, or myelodysplastic syndrome can develop secondary iron overload. Each unit of transfused blood delivers a significant dose of iron, and the body has no natural mechanism for excreting large amounts of it. Over time, the same organs are damaged in the same ways, particularly the liver, endocrine system, and heart. This form is also not autoimmune; it is simply a consequence of repeated transfusions.
How Hemochromatosis Is Detected
Diagnosis starts with blood tests measuring two values: transferrin saturation and serum ferritin. A transferrin saturation above 45 percent, or a ferritin level above 200 micrograms per liter in women or 300 in men, raises suspicion and warrants further testing. Some guidelines use slightly different cutoffs (40 percent saturation for women, 50 percent for men), so the exact threshold your doctor uses may vary slightly.
If these levels are elevated, genetic testing for HFE mutations confirms whether the cause is hereditary. Finding two copies of the C282Y mutation in someone with elevated iron markers is the most definitive diagnosis. Having the mutations alone does not guarantee you will develop symptoms, though. Only a minority of people who carry two copies of the mutation go on to develop full-blown clinical disease.
Treatment: Removing Iron, Not Suppressing Immunity
The treatment for hemochromatosis is one of the clearest signs it is not autoimmune. Autoimmune diseases are treated with immunosuppressants, drugs that dial down the immune system’s attack on healthy tissue. Hemochromatosis is treated by simply removing excess iron from the body through regular blood draws, a procedure called therapeutic phlebotomy.
During the initial phase, you typically have about 500 milliliters of blood removed once or twice a week. Each session removes roughly 200 to 250 milligrams of iron. If your iron stores are very high (some patients accumulate more than 30 grams of excess iron), this phase can take two to three years. Your ferritin level is checked every 10 to 12 sessions, and the goal is to bring it down to between 50 and 100 micrograms per liter. Doctors monitor your blood counts before each draw to make sure you don’t become anemic in the process.
Once your iron stores are depleted, you shift to maintenance phlebotomy at longer intervals, with the same ferritin target of 50 to 100. The frequency varies from person to person. You are also advised to avoid vitamin C supplements, because vitamin C enhances iron absorption and can worsen overload. Organ damage that occurred before treatment may not be fully reversible, which is why early detection matters. But with consistent phlebotomy, most people with hemochromatosis can keep iron levels in a safe range and prevent further harm.